vTv Therapeutics
VTVT
23 hedge funds and large institutions have $2.88M invested in vTv Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
17% more capital invested
Capital invested by funds: $2.47M → $2.88M (+$411K)
0.21% less ownership
Funds ownership: 4.58% → 4.37% (-0.21%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
23% less funds holding
Funds holding: 30 → 23 (-7)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13K |
| 2 |
VF
Virtu Financial
New York
|
+$9.06K |
| 3 |
FWM
Focused Wealth Management
Newburgh,
New York
|
+$4.24K |
| 4 |
SS
Sunbelt Securities
Houston,
Texas
|
+$509 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$305 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
-$38K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$25.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$20.9K |
| 4 |
Millennium Management
New York
|
-$17.2K |
| 5 |
DT
Diversified Trust
Memphis,
Tennessee
|
-$12K |
VTVT Hedge Fund Activity: Q1 2023 in Review
23 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2023, worth a combined $2.88M — up 17% from $2.47M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of VTVT and 2 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $13K. The largest seller was HBK Sorce Advisory, exiting entirely with an estimated $38K sold.
- 23 institutional investors held vTv Therapeutics (VTVT) as of Q1 2023, down from 30 in Q4 2022.
- Funds reported $2.88M of vTv Therapeutics stock for Q1 2023, up 17% quarter-over-quarter.
- 2 funds opened new vTv Therapeutics positions in Q1 2023 and 6 closed out, a net change of -4 holders.
- The largest vTv Therapeutics buyer in Q1 2023 was Susquehanna International Group, an estimated $13K added.
- The largest vTv Therapeutics seller in Q1 2023 was HBK Sorce Advisory, an estimated $38K sold.
Based on aggregated 13F filings for Q1 2023.